Fig. 6: Impact of PRL-2 silencing on VEGF signaling in vascular endothelial cells.
From: PRL-2 phosphatase is required for vascular morphogenesis and angiogenic signaling
a qPCR analysis of VEGFA in HUVEC cells after CTRL or PTP4A2 siRNA treatment (Mann–Whitney U test: *p value < 0.05; n = 5). b Effects of VEGF-A treatment on VEGFR-2 phosphorylation (p-Y1175, p-Y951) in siRNA CTRL and PTP4A2 knockdown cells. c, d Quantification of phosphorylation of VEGFR-2 Y1175 and Y951 normalized to total VEGFR-2 and compared to PBS treated control (n = 3 independent experiments; two-way ANOVA: ***p value < 0.001, ns nonsignificant p value > 0.05). e Effects of VEGF-A treatment on ERK1/2 and AKT phosphorylation in HUVECs, with CTRL siRNA and with siRNA targeting PTP4A2. f, g Quantification of p-ERK normalized to total ERK and pAKT normalized to total AKT (n = 3 independent experiments; two-way ANOVA: **p value < 0.01, ***p value < 0.001, ns nonsignificant p value > 0.05). Error bars represent mean ± s.e.m.
